✦ LIBER ✦

WITHHOLDING UNFAVOURABLE RESULTS IN DRUG COMPANY SPONSORED CLINICAL TRIALS

✍ Scribed by Lauritsen, K.; Havelund, T.; Laursen, L.S.; Rask-Madsen, J.

Book ID: 123380421
Publisher: The Lancet
Year: 1987
Tongue: English
Weight: 179 KB
Volume: 329
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(87)90515-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

UNFAVOURABLE RESULTS AND DRUG COMPANY TR

UNFAVOURABLE RESULTS AND DRUG COMPANY TRIALS

✍ Bardhan, K.D. 📂 Article 📅 1987 🏛 The Lancet 🌐 English ⚖ 177 KB

Recruitment of patients into company spo

Recruitment of patients into company sponsored clinical trials in Australia

✍ Stephen A. Cutler 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Guidelines for monitoring company sponso

Guidelines for monitoring company sponsored clinical trials in the pharmaceutical industry

✍ P.L.C. Banks 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Planning and analysis of repeated measur

Planning and analysis of repeated measures at key time-points in clinical trials sponsored by pharmaceutical companies

✍ Weichung J. Shih; Hui Quan 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

In this paper we explore the possible reasons why medical papers reporting clinical trials sponsored by the pharmaceutical industry often analyse repeated measures data at certain key time-points instead of employing sophisticated models of repeated measures proposed by many statisticians. A survey

IN45-WE-02 Antiepileptic drugs clinical

IN45-WE-02 Antiepileptic drugs clinical trials: results to practice

✍ J. French 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Drug companies should not have the final

Drug companies should not have the final say in the design of clinical trials

✍ Neil A. Kurtzman 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 16 KB